{"id":213,"date":"2023-08-23T14:51:18","date_gmt":"2023-08-23T18:51:18","guid":{"rendered":"https:\/\/ca.beyondtype2.org\/fr\/?p=213"},"modified":"2023-09-02T17:53:25","modified_gmt":"2023-09-02T21:53:25","slug":"tout-sur-les-inhibiteurs-du-sglt-2","status":"publish","type":"post","link":"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/","title":{"rendered":"Tout sur les inhibiteurs du SGLT-2"},"content":{"rendered":"<p><span style=\"font-weight: 400\">Si nous consid\u00e9rions le <\/span><a href=\"https:\/\/beyondtype2.org\/type-2-diabetes-where-do-i-start\/\"><span style=\"font-weight: 400\">diab\u00e8te de type\u00a02<\/span><\/a><span style=\"font-weight: 400\"> comme un casse-t\u00eate, nous constaterions que chacun des \u00e9l\u00e9ments est tout aussi important que les autres pour atteindre le r\u00e9sultat attendu. Nous savons que le diab\u00e8te de type\u00a02 repose sur ce que nous appelons les \u00ab\u00a0piliers de la prise en charge personnelle\u00a0\u00bb, qui comprennent <a href=\"https:\/\/www.diabetes.ca\/about-diabetes\/management-and-self-care\">sept \u00e9l\u00e9ments essentiels<\/a> dont l\u2019un est la prise de m\u00e9dicaments.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Chaque personne diab\u00e9tique a des exigences diff\u00e9rentes. Heureusement, il existe actuellement un vaste \u00e9ventail d\u2019options pour la prise en charge de la glyc\u00e9mie. Aujourd\u2019hui, nous allons parler des inhibiteurs du cotransporteur sodium-glucose de type\u00a02 (SGLT-2) et de la fa\u00e7on dont ils sont utilis\u00e9s pour aider les personnes atteintes de diab\u00e8te de type\u00a02.<\/span><\/p>\n<h3><b>Que sont les inhibiteurs du SGLT-2?<\/b><\/h3>\n<p><span style=\"font-weight: 400\">Ces m\u00e9dicaments sont \u00e9galement connus sous le nom d\u2019\u00ab inhibiteurs du cotransporteur sodium-glucose \u00bb ou de \u00ab gliflozines \u00bb. Ils comprennent Invokana (canagliflozine), Forxiga (dapagliflozine) et Jardiance (empagliflozine).<\/span><\/p>\n<p><span style=\"font-weight: 400\">Cette classe de <\/span><a href=\"https:\/\/beyondtype2.org\/access-oral-medications\/\"><span style=\"font-weight: 400\">m\u00e9dicaments oraux<\/span><\/a><span style=\"font-weight: 400\"> pour la prise en charge du diab\u00e8te de type 2 est relativement nouvelle, la canagliflozine ayant \u00e9t\u00e9 approuv\u00e9e par Sant\u00e9 Canada en 2014. Ces m\u00e9dicaments aident \u00e0 traiter le diab\u00e8te en r\u00e9duisant la r\u00e9absorption r\u00e9nale du glucose et en augmentant son \u00e9limination dans l\u2019urine, ce qui diminue les concentrations de glucose dans le sang.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Ils peuvent \u00eatre utilis\u00e9s en monoth\u00e9rapie ou en association avec d\u2019autres m\u00e9dicaments.<\/span><\/p>\n<h3><b>Fonctionnement des inhibiteurs du SGLT-2<\/b><\/h3>\n<p><span style=\"font-weight: 400\">En somme, ces m\u00e9dicaments emp\u00eachent les reins de r\u00e9absorber les concentrations de glucose dans le sang et aident le corps \u00e0 \u00e9liminer l\u2019exc\u00e8s dans l\u2019urine.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Selon l\u2019Endocrinology Network, les inhibiteurs du SGLT-2 sont des m\u00e9dicaments oraux qui r\u00e9duisent la glyc\u00e9mie de deux fa\u00e7ons.<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Ils r\u00e9duisent la quantit\u00e9 de glucose absorb\u00e9e par les reins \u00e0 excr\u00e9ter dans l\u2019urine.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Ils r\u00e9duisent la quantit\u00e9 de glucose dans la circulation sanguine.<\/span><\/li>\n<\/ul>\n<h3><b>Avantages des inhibiteurs du SGLT-2<\/b><\/h3>\n<p><b>Glyc\u00e9mie \u00e0 jeun et postprandiale\u00a0:<\/b><span style=\"font-weight: 400\"> Ces m\u00e9dicaments r\u00e9duisent \u00e0 la fois la glyc\u00e9mie \u00e0 jeun et la glyc\u00e9mie postprandiale (apr\u00e8s les repas).<\/span><\/p>\n<p><b>Diminution du risque d\u2019<\/b><a href=\"https:\/\/beyondtype2.org\/hypoglycemia-and-how-to-treat-it\/\"><b>hypoglyc\u00e9mie<\/b><\/a><b>\u00a0:<\/b><span style=\"font-weight: 400\"> En outre, ces m\u00e9dicaments ont \u00e9t\u00e9 associ\u00e9s \u00e0 une diminution du risque d\u2019hypoglyc\u00e9mie, car ils ne stimulent pas la production d\u2019insuline par le pancr\u00e9as.<\/span><\/p>\n<p><b>Perte de poids\u00a0:<\/b><span style=\"font-weight: 400\"> Selon certaines \u00e9tudes, ces m\u00e9dicaments favorisent la perte de poids.<\/span><\/p>\n<p><b>Tension art\u00e9rielle\u00a0:<\/b><span style=\"font-weight: 400\"> Un autre avantage de ces m\u00e9dicaments est qu\u2019il peuvent aider \u00e0 abaisser la tension art\u00e9rielle.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Ils sont bien tol\u00e9r\u00e9s et ont peu d\u2019effets ind\u00e9sirables intestinaux. Des donn\u00e9es probantes indiquent que ces m\u00e9dicaments procurent des bienfaits suppl\u00e9mentaires aux personnes qui pr\u00e9sentent un risque accru de maladies cardiovasculaires et une diminution des taux d\u2019HbA<\/span><span style=\"font-weight: 400\">1c<\/span><span style=\"font-weight: 400\">.<\/span><\/p>\n<h3><b>Noms de marque et caract\u00e9ristiques des inhibiteurs du SGLT-2<\/b><\/h3>\n<p><span style=\"font-weight: 400\">Sur le march\u00e9, vous pouvez trouver les inhibiteurs du SGLT2 sous diff\u00e9rents noms, chacun ayant des caract\u00e9ristiques tr\u00e8s pr\u00e9cises m\u00eame s\u2019ils agissent de fa\u00e7on semblable. Voici un tableau qui peut vous aider \u00e0 les distinguer.<\/span><\/p>\n<p><b>Dapagliflozine (Forxiga)<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Diminution des taux d\u2019h\u00e9moglobine glyqu\u00e9e (HbA<\/span><span style=\"font-weight: 400\">1c<\/span><span style=\"font-weight: 400\">) et de la glyc\u00e9mie \u00e0 jeun<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Diminution du poids corporel<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Diminution de la tension art\u00e9rielle d\u2019environ 5\u00a0mm\u00a0Hg sans augmentation de la fr\u00e9quence cardiaque<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Non\u00a0associ\u00e9 \u00e0 une toxicit\u00e9 r\u00e9nale aigu\u00eb ou \u00e0 une alt\u00e9ration de la fonction r\u00e9nale<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Risque non\u00a0significatif d\u2019hypoglyc\u00e9mie<\/span><\/li>\n<\/ul>\n<p><b>Canagliflozine (Invokana)\u00a0<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">R\u00e9duction significative des taux d\u2019h\u00e9moglobine glyqu\u00e9e (HbA<\/span><span style=\"font-weight: 400\">1C<\/span><span style=\"font-weight: 400\">) et de la glyc\u00e9mie \u00e0 jeun<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">L\u00e9g\u00e8re diminution du poids corporel<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Diminution entre 0,8 et 6,8\u00a0mm\u00a0Hg de la tension art\u00e9rielle systolique<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Faible taux d\u2019hypoglyc\u00e9mie en monoth\u00e9rapie, mais plus \u00e9lev\u00e9 en association avec de l\u2019insuline ou des sulfonylur\u00e9es<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Pr\u00e9sence d\u2019infections g\u00e9nitales fongiques et d\u2019infections urinaires d\u2019intensit\u00e9 l\u00e9g\u00e8re ou mod\u00e9r\u00e9e, surtout chez les femmes<\/span><\/li>\n<\/ul>\n<p><b>Empagliflozine (Jardiance)\u00a0<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">R\u00e9duction significative des taux d\u2019h\u00e9moglobine glyqu\u00e9e (HbA<\/span><span style=\"font-weight: 400\">1C<\/span><span style=\"font-weight: 400\">) et de la glyc\u00e9mie \u00e0 jeun<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">R\u00e9duction du poids corporel<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">R\u00e9duction de 2 \u00e0 5\u00a0mm\u00a0Hg de la tension art\u00e9rielle systolique apr\u00e8s 24\u00a0semaines<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Faible taux d\u2019hypoglyc\u00e9mie en monoth\u00e9rapie, mais plus \u00e9lev\u00e9 en association avec de l\u2019insuline ou des sulfonylur\u00e9es<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Apr\u00e8s 24\u00a0semaines, des infections urinaires ont \u00e9t\u00e9 signal\u00e9es chez 8 \u00e0 10\u00a0% des patients, et entre 2,3 et 2,7\u00a0% dans le cas des infections g\u00e9nitales<\/span><\/li>\n<\/ul>\n<p><b>Ipragliflozine (Sugalet)<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Actuellement mis au point au Japon.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Diminution importante du taux d\u2019HbA<\/span><span style=\"font-weight: 400\">1c<\/span><span style=\"font-weight: 400\"> et de la glyc\u00e9mie \u00e0 jeun apr\u00e8s 12 et 24\u00a0semaines<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Diminution du poids de 1,47\u00a0kg apr\u00e8s 16\u00a0semaines d\u2019utilisation<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Apr\u00e8s 12 \u00e0 16\u00a0semaines, une diminution de 3,2 \u00e0 4,3\u00a0mm\u00a0Hg de la pression systolique a \u00e9t\u00e9 observ\u00e9e<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Une hypoglyc\u00e9mie a \u00e9t\u00e9 signal\u00e9e dans une proportion de 1 \u00e0 5,9\u00a0%<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Les infections des voies urinaires \u00e9taient rares, tandis que les infections g\u00e9nitales \u00e9taient plus fr\u00e9quentes, chez 3 \u00e0 4,3\u00a0% des patients<\/span><\/li>\n<\/ul>\n<h3><b>Quels sont les effets secondaires?<\/b><\/h3>\n<p><span style=\"font-weight: 400\">Les infections des voies urinaires ont \u00e9t\u00e9 signal\u00e9es parmi les effets secondaires. L\u2019acidoc\u00e9tose diab\u00e9tique fait \u00e9galement partie des effets secondaires signal\u00e9s.<\/span><\/p>\n<h3><b>Conclusion<\/b><\/h3>\n<p><span style=\"font-weight: 400\">Les inhibiteurs du cotransporteur sodium-glucose de type\u00a02 (SGLT-2) font partie d\u2019un nouveau traitement pour la prise en charge du diab\u00e8te et sont ind\u00e9pendants de la s\u00e9cr\u00e9tion et de la fonction de l\u2019insuline. Des \u00e9tudes ont montr\u00e9 qu\u2019ils sont efficaces et s\u00fbrs en association avec d\u2019autres m\u00e9dicaments oraux comme la metformine, les sulfonylur\u00e9es et les thiazolidin\u00e9diones, ainsi qu\u2019avec les inhibiteurs de la dipeptidyl peptidase-4 (DPP-4) ou l\u2019insuline.<\/span><\/p>\n<p><b>R\u00e9f\u00e9rences\u00a0:\u00a0<\/b><\/p>\n<p><span style=\"font-weight: 400\">https:\/\/www.endocrinologynetwork.com\/news<\/span><\/p>\n<p><span style=\"font-weight: 400\">https:\/\/www.jacc.org\/doi\/full\/10.1016\/j.jacbts.2020.02.004<\/span><\/p>\n<p><span style=\"font-weight: 400\">https:\/\/www.nejm.org\/doi\/10.1056 \/ NEJMoa1611925<\/span><\/p>\n<p><span style=\"font-weight: 400\">http:\/\/www.scielo.org.mx\/scielo.php?script=sci_arttext&amp;pid=S0186-48662017000300363<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Si nous consid\u00e9rions le diab\u00e8te de type\u00a02 comme un casse-t\u00eate, nous constaterions que chacun des \u00e9l\u00e9ments est tout aussi important que les autres pour atteindre le r\u00e9sultat attendu. Nous savons que le diab\u00e8te de type\u00a02 repose sur ce que nous appelons les \u00ab\u00a0piliers de la prise en charge personnelle\u00a0\u00bb, qui comprennent sept \u00e9l\u00e9ments essentiels dont [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":216,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"invisible":[8,80,5],"class_list":["post-213","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles-pour-les-nouvellement-diagnostiques-avec-le-diabete","invisible-core-evergreen-resource","invisible-hearthealth","invisible-thebasicbasics"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Tout sur les inhibiteurs du SGLT-2 - Beyond Type 2 Canada<\/title>\n<meta name=\"description\" content=\"Les inhibiteurs du SGLT-2 font partie des options de traitement pour la prise en charge du diab\u00e8te de type\u00a02. D\u00e9couvrez les noms de marque, les bienfaits et les effets secondaires de ces m\u00e9dicaments.\u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tout sur les inhibiteurs du SGLT-2 - Beyond Type 2 Canada\" \/>\n<meta property=\"og:description\" content=\"Les inhibiteurs du SGLT-2 font partie des options de traitement pour la prise en charge du diab\u00e8te de type\u00a02. D\u00e9couvrez les noms de marque, les bienfaits et les effets secondaires de ces m\u00e9dicaments.\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Beyond Type 2 Canada\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-23T18:51:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-02T21:53:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ca.beyondtype2.org\/fr\/wp-content\/uploads\/sites\/2\/2023\/08\/BT2-HEADER-ORAL-MEDS-1-1200x429-1-768x275-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"768\" \/>\n\t<meta property=\"og:image:height\" content=\"275\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"karime\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"karime\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/\"},\"author\":{\"name\":\"karime\",\"@id\":\"https:\/\/ca.beyondtype2.org\/fr\/#\/schema\/person\/d91e9ec1795266e38d9960b69579490c\"},\"headline\":\"Tout sur les inhibiteurs du SGLT-2\",\"datePublished\":\"2023-08-23T18:51:18+00:00\",\"dateModified\":\"2023-09-02T21:53:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/\"},\"wordCount\":989,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ca.beyondtype2.org\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ca.beyondtype2.org\/fr\/wp-content\/uploads\/sites\/2\/2023\/08\/BT2-HEADER-ORAL-MEDS-1-1200x429-1-768x275-1.jpeg\",\"articleSection\":[\"Nouvellement diagnostiqu\u00e9\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/\",\"url\":\"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/\",\"name\":\"Tout sur les inhibiteurs du SGLT-2 - Beyond Type 2 Canada\",\"isPartOf\":{\"@id\":\"https:\/\/ca.beyondtype2.org\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ca.beyondtype2.org\/fr\/wp-content\/uploads\/sites\/2\/2023\/08\/BT2-HEADER-ORAL-MEDS-1-1200x429-1-768x275-1.jpeg\",\"datePublished\":\"2023-08-23T18:51:18+00:00\",\"dateModified\":\"2023-09-02T21:53:25+00:00\",\"description\":\"Les inhibiteurs du SGLT-2 font partie des options de traitement pour la prise en charge du diab\u00e8te de type\u00a02. D\u00e9couvrez les noms de marque, les bienfaits et les effets secondaires de ces m\u00e9dicaments.\u00a0\",\"breadcrumb\":{\"@id\":\"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/#primaryimage\",\"url\":\"https:\/\/ca.beyondtype2.org\/fr\/wp-content\/uploads\/sites\/2\/2023\/08\/BT2-HEADER-ORAL-MEDS-1-1200x429-1-768x275-1.jpeg\",\"contentUrl\":\"https:\/\/ca.beyondtype2.org\/fr\/wp-content\/uploads\/sites\/2\/2023\/08\/BT2-HEADER-ORAL-MEDS-1-1200x429-1-768x275-1.jpeg\",\"width\":768,\"height\":275},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ca.beyondtype2.org\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tout sur les inhibiteurs du SGLT-2\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ca.beyondtype2.org\/fr\/#website\",\"url\":\"https:\/\/ca.beyondtype2.org\/fr\/\",\"name\":\"Beyond Type 2 Canada\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/ca.beyondtype2.org\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ca.beyondtype2.org\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ca.beyondtype2.org\/fr\/#organization\",\"name\":\"Beyond Type 2 Canada\",\"url\":\"https:\/\/ca.beyondtype2.org\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ca.beyondtype2.org\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ca.beyondtype2.org\/fr\/wp-content\/uploads\/sites\/2\/2023\/08\/bt2-logo-v2.png\",\"contentUrl\":\"https:\/\/ca.beyondtype2.org\/fr\/wp-content\/uploads\/sites\/2\/2023\/08\/bt2-logo-v2.png\",\"width\":380,\"height\":83,\"caption\":\"Beyond Type 2 Canada\"},\"image\":{\"@id\":\"https:\/\/ca.beyondtype2.org\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ca.beyondtype2.org\/fr\/#\/schema\/person\/d91e9ec1795266e38d9960b69579490c\",\"name\":\"karime\",\"url\":\"https:\/\/ca.beyondtype2.org\/fr\/author\/karime\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tout sur les inhibiteurs du SGLT-2 - Beyond Type 2 Canada","description":"Les inhibiteurs du SGLT-2 font partie des options de traitement pour la prise en charge du diab\u00e8te de type\u00a02. D\u00e9couvrez les noms de marque, les bienfaits et les effets secondaires de ces m\u00e9dicaments.\u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/","og_locale":"en_US","og_type":"article","og_title":"Tout sur les inhibiteurs du SGLT-2 - Beyond Type 2 Canada","og_description":"Les inhibiteurs du SGLT-2 font partie des options de traitement pour la prise en charge du diab\u00e8te de type\u00a02. D\u00e9couvrez les noms de marque, les bienfaits et les effets secondaires de ces m\u00e9dicaments.\u00a0","og_url":"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/","og_site_name":"Beyond Type 2 Canada","article_published_time":"2023-08-23T18:51:18+00:00","article_modified_time":"2023-09-02T21:53:25+00:00","og_image":[{"width":768,"height":275,"url":"https:\/\/ca.beyondtype2.org\/fr\/wp-content\/uploads\/sites\/2\/2023\/08\/BT2-HEADER-ORAL-MEDS-1-1200x429-1-768x275-1.jpeg","type":"image\/jpeg"}],"author":"karime","twitter_card":"summary_large_image","twitter_misc":{"Written by":"karime","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/#article","isPartOf":{"@id":"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/"},"author":{"name":"karime","@id":"https:\/\/ca.beyondtype2.org\/fr\/#\/schema\/person\/d91e9ec1795266e38d9960b69579490c"},"headline":"Tout sur les inhibiteurs du SGLT-2","datePublished":"2023-08-23T18:51:18+00:00","dateModified":"2023-09-02T21:53:25+00:00","mainEntityOfPage":{"@id":"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/"},"wordCount":989,"commentCount":0,"publisher":{"@id":"https:\/\/ca.beyondtype2.org\/fr\/#organization"},"image":{"@id":"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/#primaryimage"},"thumbnailUrl":"https:\/\/ca.beyondtype2.org\/fr\/wp-content\/uploads\/sites\/2\/2023\/08\/BT2-HEADER-ORAL-MEDS-1-1200x429-1-768x275-1.jpeg","articleSection":["Nouvellement diagnostiqu\u00e9"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/","url":"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/","name":"Tout sur les inhibiteurs du SGLT-2 - Beyond Type 2 Canada","isPartOf":{"@id":"https:\/\/ca.beyondtype2.org\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/#primaryimage"},"image":{"@id":"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/#primaryimage"},"thumbnailUrl":"https:\/\/ca.beyondtype2.org\/fr\/wp-content\/uploads\/sites\/2\/2023\/08\/BT2-HEADER-ORAL-MEDS-1-1200x429-1-768x275-1.jpeg","datePublished":"2023-08-23T18:51:18+00:00","dateModified":"2023-09-02T21:53:25+00:00","description":"Les inhibiteurs du SGLT-2 font partie des options de traitement pour la prise en charge du diab\u00e8te de type\u00a02. D\u00e9couvrez les noms de marque, les bienfaits et les effets secondaires de ces m\u00e9dicaments.\u00a0","breadcrumb":{"@id":"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/#primaryimage","url":"https:\/\/ca.beyondtype2.org\/fr\/wp-content\/uploads\/sites\/2\/2023\/08\/BT2-HEADER-ORAL-MEDS-1-1200x429-1-768x275-1.jpeg","contentUrl":"https:\/\/ca.beyondtype2.org\/fr\/wp-content\/uploads\/sites\/2\/2023\/08\/BT2-HEADER-ORAL-MEDS-1-1200x429-1-768x275-1.jpeg","width":768,"height":275},{"@type":"BreadcrumbList","@id":"https:\/\/ca.beyondtype2.org\/fr\/tout-sur-les-inhibiteurs-du-sglt-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ca.beyondtype2.org\/fr\/"},{"@type":"ListItem","position":2,"name":"Tout sur les inhibiteurs du SGLT-2"}]},{"@type":"WebSite","@id":"https:\/\/ca.beyondtype2.org\/fr\/#website","url":"https:\/\/ca.beyondtype2.org\/fr\/","name":"Beyond Type 2 Canada","description":"","publisher":{"@id":"https:\/\/ca.beyondtype2.org\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ca.beyondtype2.org\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ca.beyondtype2.org\/fr\/#organization","name":"Beyond Type 2 Canada","url":"https:\/\/ca.beyondtype2.org\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ca.beyondtype2.org\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ca.beyondtype2.org\/fr\/wp-content\/uploads\/sites\/2\/2023\/08\/bt2-logo-v2.png","contentUrl":"https:\/\/ca.beyondtype2.org\/fr\/wp-content\/uploads\/sites\/2\/2023\/08\/bt2-logo-v2.png","width":380,"height":83,"caption":"Beyond Type 2 Canada"},"image":{"@id":"https:\/\/ca.beyondtype2.org\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ca.beyondtype2.org\/fr\/#\/schema\/person\/d91e9ec1795266e38d9960b69579490c","name":"karime","url":"https:\/\/ca.beyondtype2.org\/fr\/author\/karime\/"}]}},"featured_image_src":"https:\/\/ca.beyondtype2.org\/fr\/wp-content\/uploads\/sites\/2\/2023\/08\/BT2-HEADER-ORAL-MEDS-1-1200x429-1-768x275-1-600x275.jpeg","featured_image_src_square":"https:\/\/ca.beyondtype2.org\/fr\/wp-content\/uploads\/sites\/2\/2023\/08\/BT2-HEADER-ORAL-MEDS-1-1200x429-1-768x275-1-600x275.jpeg","author_info":{"display_name":"karime","author_link":"https:\/\/ca.beyondtype2.org\/fr\/author\/karime\/"},"jetpack_featured_media_url":"https:\/\/ca.beyondtype2.org\/fr\/wp-content\/uploads\/sites\/2\/2023\/08\/BT2-HEADER-ORAL-MEDS-1-1200x429-1-768x275-1.jpeg","_links":{"self":[{"href":"https:\/\/ca.beyondtype2.org\/fr\/wp-json\/wp\/v2\/posts\/213","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ca.beyondtype2.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ca.beyondtype2.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ca.beyondtype2.org\/fr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/ca.beyondtype2.org\/fr\/wp-json\/wp\/v2\/comments?post=213"}],"version-history":[{"count":0,"href":"https:\/\/ca.beyondtype2.org\/fr\/wp-json\/wp\/v2\/posts\/213\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ca.beyondtype2.org\/fr\/wp-json\/wp\/v2\/media\/216"}],"wp:attachment":[{"href":"https:\/\/ca.beyondtype2.org\/fr\/wp-json\/wp\/v2\/media?parent=213"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ca.beyondtype2.org\/fr\/wp-json\/wp\/v2\/categories?post=213"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ca.beyondtype2.org\/fr\/wp-json\/wp\/v2\/tags?post=213"},{"taxonomy":"invisible","embeddable":true,"href":"https:\/\/ca.beyondtype2.org\/fr\/wp-json\/wp\/v2\/invisible?post=213"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}